<DOC>
	<DOCNO>NCT00574873</DOCNO>
	<brief_summary>Two-arm , randomize , open-label trial design evaluate efficacy safety bosutinib alone compare imatinib alone subject newly diagnose chronic phase Chronic Myelogenous Leukemia ( CML ) . The primary endpoint cytogenetic response rate one year .</brief_summary>
	<brief_title>Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Cytogenetic diagnosis chronic phase Ph+ CML diagnose less 6 month . Diagnosis CML chronic phase confirm . Adequate hepatic renal function . Able take oral tablet . Exclusions include Philadelphia negative CML . Prior antileukemia treatment . Prior stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>imatinib</keyword>
	<keyword>CML</keyword>
</DOC>